Activation of δ- and κ-opioid receptors by opioid peptides protects cardiomyocytes via KATP channels

被引:47
作者
Cao, ZP
Liu, LJ
Van Winkle, DM
机构
[1] Oregon Hlth Sci Univ, Vet Affairs Med Ctr, Anesthesiol Serv, Portland, OR 97201 USA
[2] Oregon Hlth Sci Univ, Vet Affairs Med Ctr, Res Serv, Portland, OR 97201 USA
[3] Oregon Hlth Sci Univ, Dept Anesthesiol, Portland, OR 97201 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 2003年 / 285卷 / 03期
关键词
heart; ischemic preconditioning; hypoxia;
D O I
10.1152/ajpheart.01004.2002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To examine the receptor specificity and the mechanism of opioid peptide-induced protection, we examined freshly isolated adult rabbit cardiomyocytes subjected to simulated ischemia. Cell death as a function of time was assessed by trypan blue permeability. Dynorphin B (DynB) and Met(5)-enkephalin ( ME) limitation of cell death ( expressed as area under the curve) was sensitive to blockade by naltrindole (NTI, a delta-selective antagonist) and 5'-guanidinyl-17-(cyclopropylmethyl)-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7-2',3'-indolomorphinan (GNTI dihydrochloride, a kappa-selective antagonist): 85.7 +/- 2.7 and 142.9 +/- 2.7 with DynB and DynB + NTI, respectively (P < 0.001), 94.1 ± 4.2 and 164.5 ± 7.3 with DynB and DynB ± GNTI, respectively (P < 0.001), 111.9 +/- 7.0 and 192.1 +/- 6.4 with ME and ME + NTI, respectively (P < 0.001), and 120.2 ± 4.3 and 170.0 ± 3.3 with ME and ME + GNTI, respectively (P < 0.001). Blockade of ATP-sensitive K+ channels eliminated DynB- and ME-induced protection: 189.6 +/- 5.4 and 139.0 +/- 5.4 for control and ME, respectively (P < 0.001), and 210 ± 5.9 and 195 ± 6.1 for 5-HD and ME ± 5-HD, respectively (P < 0.001); 136.0 +/- 5.7 and 63.4 +/- 5.4 for control and ME, respectively (P < 0.001), and 144.6 ± 4.5 and 114.6 ± 7.7 for HMR-1098 and ME + HMR-1098, respectively (P < 0.01); 189.6 +/- 5.4 and 139.0 +/- 5.4 for control and ME, respectively (P < 0.001), and 210 ± 5.9 and 195 ± 6.1 for 5-HD and ME + 5-HD, respectively (P < 0.001); and 136.0 +/- 5.7 and 63.4 +/- 5.4 for control and ME, respectively (P < 0.001), and 144.6 ± 4.5 and 114.6 ± 7.7 for HMR-1098 and ME + HMR-1098, respectively (P < 0.01). We conclude that opioid peptide-induced cardioprotection is mediated by delta- and kappa-receptors and involves sarcolemmal and mitochondrial ATP-sensitive K+ channels.
引用
收藏
页码:H1032 / H1039
页数:8
相关论文
共 58 条
[1]   Endogenous opioids: overview and current issues [J].
Akil, H ;
Owens, C ;
Gutstein, H ;
Taylor, L ;
Curran, E ;
Watson, S .
DRUG AND ALCOHOL DEPENDENCE, 1998, 51 (1-2) :127-140
[2]   EFFECTS OF 2,3-BUTANEDIONE MONOXIME (BDM) ON CONTRACTURE AND INJURY OF ISOLATED RAT MYOCYTES FOLLOWING METABOLIC INHIBITION AND ISCHEMIA [J].
ARMSTRONG, SC ;
GANOTE, CE .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1991, 23 (09) :1001-1014
[3]   Naloxone blockade of myocardial ischemic preconditioning does not require central nervous system participation [J].
Chien, GL ;
Mohtadi, K ;
Wolff, RA ;
Van Winkle, DM .
BASIC RESEARCH IN CARDIOLOGY, 1999, 94 (02) :136-143
[4]   Naloxone blockade of myocardial ischemic preconditioning is stereoselective [J].
Chien, GL ;
VanWinkle, DM .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1996, 28 (09) :1895-1900
[5]   Ischemic preconditioning:: From adenosine receptor to KATP channel [J].
Cohen, MV ;
Baines, CP ;
Downey, JM .
ANNUAL REVIEW OF PHYSIOLOGY, 2000, 62 :79-109
[6]   PRIMARY STRUCTURE OF THE HUMAN MET-ENKEPHALIN AND LEU-ENKEPHALIN PRECURSOR AND ITS MESSENGER-RNA [J].
COMB, M ;
SEEBURG, PH ;
ADELMAN, J ;
EIDEN, L ;
HERBERT, E .
NATURE, 1982, 295 (5851) :663-666
[7]   DEMONSTRATION BY INSITU HYBRIDIZATION OF THE PROOPIOMELANOCORTIN GENE IN THE RAT-HEART [J].
FORMAN, LJ ;
BAGASRA, O .
BRAIN RESEARCH BULLETIN, 1992, 28 (03) :441-445
[8]   Essential activation of PKC-δ in opioid-initiated cardioprotection [J].
Fryer, RM ;
Wang, YG ;
Hsu, AK ;
Gross, GJ .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2001, 280 (03) :H1346-H1353
[9]  
Fryer RM, 2000, J PHARMACOL EXP THER, V294, P451
[10]  
GOLDSTEIN A, 1984, MOL PHARMACOL, V25, P343